BRIEF-Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook

Reuters
Jan 12
BRIEF-<a href="https://laohu8.com/S/BCAX">Bicara Therapeutics</a> Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook

Jan 12 (Reuters) - Bicara Therapeutics Inc BCAX.O:

  • BICARA THERAPEUTICS ANNOUNCES PHASE 3 OPTIMAL DOSE AND PROVIDES 2026 CORPORATE OUTLOOK

  • BICARA THERAPEUTICS - EXPECTS TO ACHIEVE SUBSTANTIAL ENROLLMENT IN FORTIFI-HN01 IN 2026 TO ENABLE INTERIM ANALYSIS IN MID-2027

  • BICARA THERAPEUTICS INC - ANTICIPATES MULTIPLE DATA READOUTS IN 2026 FOR FICERAFUSP ALFA

Source text: ID:nGNX4D2nGr

Further company coverage: BCAX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10